Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...
Johnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of ...
The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in ...
A new study published in Psychological Medicine sheds light on how specific depression symptoms are related to decisions ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
Scientists at Virginia Tech are revolutionizing depression treatment by tapping into how the brain processes rewards. Their ...
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...
A non-invasive form of treatment for clinical depression is hoping to provide even faster results thanks to new research.
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
Biochemical analyses provide an answer to the question of how the gut bacterium Morganella morganii might contribute to some ...